The European Medicines Agency (EMA) has approved Cabozantinib as a second-line treatment option for patients with advanced renal cell carcinoma (RCC) who have previously been treated with vascular endothelial growth factor (VEGF)-targeted therapy. Read more.
Novel targeted and immunological therapies may help improve the outlook for patients with renal cell carcinoma (RCC), according to Dr Basma Greef, of the department of oncology at the Cambridge University Hospitals NHS Foundation Trust in the United Kingdom. She [...]
A study of the U.S. Surveillance, Epidemiology and End Results (SEER) registry 2001-2009 data shows that surgery continues to be the most common treatment, with nephron-sparing surgery exceeding radical nephrectomy. Dr. william C. Huang, Feinberg School of Medicine, Northwestern University, [...]
by Deb Maskens, Kidney Cancer Canada The American Society of Clinical Oncology (ASCO) held its annual Genitourinary (GU) Cancers Symposium in San Francisco from January 7-9. The theme of this year’s Symposium was “Patient-Centric Care: Translating Research to Results”. The [...]
Has Immune Checkpoint blockade re-established immunotherapy as a Key Pillar of Kidney cancer care? A panel led by Dr. Michael Atkins discusses the current state of immuno-oncology for kidney cancer.